Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.
about
DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modificationshSirT1-dependent regulation of the PCAF-E2F1-p73 apoptotic pathway in response to DNA damageThe Bcl-2 apoptotic switch in cancer development and therapyRegulation of Bim in Health and DiseaseTo live or let die - complexity within the E2F1 pathwayUnderstanding pRb: toward the necessary development of targeted treatments for retinoblastomaDivergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor developmentMechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemiaGene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancerThe sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activityTrichostatin A targets the mitochondrial respiratory chain, increasing mitochondrial reactive oxygen species production to trigger apoptosis in human breast cancer cellsConditional deletion of the retinoblastoma (Rb) gene in ovarian granulosa cells leads to premature ovarian failure.Identification of a candidate alternative promoter region of the human Bcl2L11 (Bim) geneE2F and p53 induce apoptosis independently during Drosophila development but intersect in the context of DNA damage.Dual regulation of Cdc25A by Chk1 and p53-ATF3 in DNA replication checkpoint control.Largazole Arrests Cell Cycle at G1 Phase and Triggers Proteasomal Degradation of E2F1 in Lung Cancer Cells.Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells.Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells.Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer.Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types.Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies.Polyphenols and the modulation of gene expression pathways: can we eat our way out of the danger of chronic disease?Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors.Lung cancer therapeutics that target signaling pathways: an update.Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cellsE2F transcription factor 1 regulates cellular and organismal senescence by inhibiting Forkhead box O transcription factorsHDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure.Antitumor activity of SAHA, a novel histone deacetylase inhibitor, against murine B cell lymphoma A20 cells in vitro and in vivo.Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.Impairment of organ-specific T cell negative selection by diabetes susceptibility genes: genomic analysis by mRNA profilingHistone deacetylase inhibitors induce apoptosis in both Type I and Type II endometrial cancer cells.Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphomaHistone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy.
P2860
Q24319915-9AF3DAC9-E341-4F87-940F-599D9E630309Q24329260-351A952D-8F70-4160-AB7A-9DBE81AE43E8Q24620437-4E93E5A3-8139-41EC-AA7C-DBDA56937CFEQ26781203-EB0B28DF-9A29-4F8C-BC61-7909C7121E11Q26862588-794DECAD-E681-40B8-AC38-FCE1AB373833Q27011911-4D7B5026-031D-4017-98BE-67762C60C1F9Q28384678-BFD73B16-5210-47E0-B09E-FF99C7CFE4C2Q28385690-79782032-2170-4E16-ACE2-07C0992F379DQ28477038-281CDEFF-4CFD-4F3B-A008-C5576350702CQ28487756-CFDA7C7E-F19F-4D87-89D6-B263F2C53621Q28540870-29817C14-01E8-45EF-9AC2-1C4680EB9B8DQ30438817-86BCF2F6-05A8-4B15-88E7-3F393C8013B3Q33343257-4ECB4E40-B27F-4805-8848-736AF80D958CQ33358684-E7F48944-EE77-431F-9505-C3BA5E22AB9DQ33390327-CEB8AAEC-F324-4F2E-AABD-2764AF993B63Q33636007-1FEDACD1-8722-49E4-8E85-445CC5AD2C00Q33705588-032C637B-938B-4387-A43C-D8FD941929DBQ33829390-69F2C487-81B0-431A-8A96-9C6DC13768BEQ33831971-47C5E5CA-F1C3-465D-8DFC-9F5B1705D694Q33911230-D16F5360-1F46-4F24-A05E-5BE43B543FA0Q33983255-FDCC5811-6D5A-40FA-9836-25214F80275BQ34114810-A1AB9714-CF87-403F-B976-AF121196B7DFQ34171631-C90B695D-D8F4-4517-A47E-64581F085347Q34199935-2519B762-CA2F-4105-B12F-BD59F603F0F1Q34224278-41D8A36B-5311-49AD-A9E7-26C39D8540F4Q34240470-BC748713-B8D4-4867-A48D-1B904A499E72Q34344158-88C908E7-1660-4AEE-9434-A1A6EF4AD265Q34399444-6DD160E7-55E5-42AF-9825-1EEBCB14015DQ34402471-E95455EE-E1D8-4421-A556-54418A067289Q34416994-22E8AC74-73A5-4C68-A87D-EF57CE3274ECQ34541960-F4952972-2656-456E-BB20-16F6DE8A6C6BQ34619655-1A0C1BF7-89EA-4FD2-B4DD-90CA105D0530Q34634278-8C555F59-F906-40F5-A672-75E0EAF21501Q34749665-50808BDF-B025-4AF7-A4D5-213D79D0522FQ35554901-AD3FBA6B-CB89-43BD-8F0B-5FFA2CECD8D4Q35706804-847D35F7-5EE7-493E-818D-C227917779B9Q35724760-20A97C1C-7393-43BF-A8A1-43645635E62FQ35739692-22AFF1F7-E0D2-4807-B316-4FB33C0D12D2Q35808910-A1F7E19F-CC4D-4ED1-861A-9981945760AFQ35856816-EB0DC2F5-A47D-4870-818F-59756C1EDCF9
P2860
Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Inhibitors of histone deacetyl ...... n of proapoptotic protein Bim.
@ast
Inhibitors of histone deacetyl ...... n of proapoptotic protein Bim.
@en
Inhibitors of histone deacetyl ...... n of proapoptotic protein Bim.
@nl
type
label
Inhibitors of histone deacetyl ...... n of proapoptotic protein Bim.
@ast
Inhibitors of histone deacetyl ...... n of proapoptotic protein Bim.
@en
Inhibitors of histone deacetyl ...... n of proapoptotic protein Bim.
@nl
prefLabel
Inhibitors of histone deacetyl ...... n of proapoptotic protein Bim.
@ast
Inhibitors of histone deacetyl ...... n of proapoptotic protein Bim.
@en
Inhibitors of histone deacetyl ...... n of proapoptotic protein Bim.
@nl
P2093
P2860
P356
P1476
Inhibitors of histone deacetyl ...... n of proapoptotic protein Bim.
@en
P2093
P2860
P304
16090-16095
P356
10.1073/PNAS.0505585102
P407
P577
2005-10-21T00:00:00Z